CN104220451B - 具有hiv成熟抑制活性的c-3环烯三萜类化合物 - Google Patents

具有hiv成熟抑制活性的c-3环烯三萜类化合物 Download PDF

Info

Publication number
CN104220451B
CN104220451B CN201380019696.6A CN201380019696A CN104220451B CN 104220451 B CN104220451 B CN 104220451B CN 201380019696 A CN201380019696 A CN 201380019696A CN 104220451 B CN104220451 B CN 104220451B
Authority
CN
China
Prior art keywords
pentamethyl
mixture
prop
alkyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380019696.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN104220451A (zh
Inventor
J.斯维多斯基
N.A.米恩维尔
A.里古尔罗-伦
S-Y.希特
J.陈
Y.陈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Health Uk Fifth Ltd
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48946098&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104220451(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Priority to CN201610397768.6A priority Critical patent/CN106046106A/zh
Publication of CN104220451A publication Critical patent/CN104220451A/zh
Application granted granted Critical
Publication of CN104220451B publication Critical patent/CN104220451B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J63/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008Expansion of ring D by one atom, e.g. D homo steroids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J53/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002Carbocyclic rings fused
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201380019696.6A 2012-02-15 2013-02-13 具有hiv成熟抑制活性的c-3环烯三萜类化合物 Expired - Fee Related CN104220451B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610397768.6A CN106046106A (zh) 2012-02-15 2013-02-13 具有hiv成熟抑制活性的c‑3环烯三萜类化合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261599040P 2012-02-15 2012-02-15
US61/599,040 2012-02-15
US13/760,726 US8906889B2 (en) 2012-02-15 2013-02-06 C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity
US13/760,726 2013-02-06
PCT/US2013/025897 WO2013123019A1 (en) 2012-02-15 2013-02-13 C-3 cycloalkenyl triterpenoids with hiv maturation inhibitory activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201610397768.6A Division CN106046106A (zh) 2012-02-15 2013-02-13 具有hiv成熟抑制活性的c‑3环烯三萜类化合物

Publications (2)

Publication Number Publication Date
CN104220451A CN104220451A (zh) 2014-12-17
CN104220451B true CN104220451B (zh) 2016-06-29

Family

ID=48946098

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380019696.6A Expired - Fee Related CN104220451B (zh) 2012-02-15 2013-02-13 具有hiv成熟抑制活性的c-3环烯三萜类化合物
CN201610397768.6A Pending CN106046106A (zh) 2012-02-15 2013-02-13 具有hiv成熟抑制活性的c‑3环烯三萜类化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201610397768.6A Pending CN106046106A (zh) 2012-02-15 2013-02-13 具有hiv成熟抑制活性的c‑3环烯三萜类化合物

Country Status (26)

Country Link
US (1) US8906889B2 (enExample)
EP (1) EP2814834B1 (enExample)
JP (1) JP6155285B2 (enExample)
KR (1) KR20140123584A (enExample)
CN (2) CN104220451B (enExample)
AR (1) AR089996A1 (enExample)
AU (1) AU2013221725B2 (enExample)
BR (1) BR112014019672A8 (enExample)
CA (1) CA2864656A1 (enExample)
CL (1) CL2014002141A1 (enExample)
CO (1) CO7061077A2 (enExample)
EA (1) EA024361B1 (enExample)
ES (1) ES2656984T3 (enExample)
HK (1) HK1204608A1 (enExample)
IL (1) IL234077A (enExample)
MX (1) MX2014009235A (enExample)
MY (1) MY166793A (enExample)
NZ (1) NZ631408A (enExample)
PE (1) PE20142315A1 (enExample)
PH (1) PH12014501816A1 (enExample)
PT (1) PT2814834T (enExample)
SG (1) SG11201404748XA (enExample)
TW (1) TW201336863A (enExample)
UY (1) UY34627A (enExample)
WO (1) WO2013123019A1 (enExample)
ZA (1) ZA201406724B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889854B2 (en) 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity
SG11201505639SA (en) 2013-02-06 2015-08-28 Bristol Myers Squibb Co C-19 modified triterpenoids with hiv maturation inhibitory activity
PL3129392T3 (pl) 2014-04-11 2021-04-06 VIIV Healthcare UK(No.4) Limited Triterpenoidy o aktywności hamującej dojrzewanie hiv, podstawione w pozycji 3 niearomatycznym pierścieniem zawierającym podstawnik fluorowcoalkilowy
WO2015195776A1 (en) 2014-06-19 2015-12-23 Bristol-Myers Squibb Company Betulinic acid derivatives with hiv maturation inhibitory activity
US10047118B2 (en) 2014-11-14 2018-08-14 VIIV Healthcare UK (No.5) Limited C17-aryl substituted betulinic acid analogs
US9969767B2 (en) 2014-11-14 2018-05-15 VIIV Healthcare UK (No.5) Limited Oxolupene derivatives
CN107250151A (zh) * 2014-11-14 2017-10-13 Viiv保健英国第五有限公司 扩展的桦木酸类似物
US10221208B2 (en) * 2015-04-14 2019-03-05 ViiV Healthcare UK (No.4) Limited Methods of producing an HIV maturation inhibitor
WO2017017609A1 (en) 2015-07-28 2017-02-02 Glaxosmithkline Intellectual Property (No.2) Limited Betuin derivatives for preventing or treating hiv infections
CA2993758A1 (en) 2015-07-28 2017-02-02 Glaxosmithkline Intellectual Property (No.2) Limited Betuin derivatives for preventing or treating hiv infections
AU2016327169A1 (en) 2015-09-24 2018-04-12 Glaxosmithkline Intellectual Property (No.2) Limited Compounds with hiv maturation inhibitory activity
EP3405474A1 (en) * 2016-01-20 2018-11-28 Glaxosmithkline Intellectual Property (No. 2) Limited Amine derivatives of lupanes with hiv maturation inhibitory activity
AR107512A1 (es) * 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
CN106905264B (zh) * 2017-04-12 2019-06-07 连云港杰瑞药业有限公司 一种合成阿扎拉韦中间体的方法
IL273078B2 (en) * 2017-09-13 2025-06-01 Emmyon Inc Ursolic acid morpholine and diethanolamine salts
EP4321164A3 (en) 2018-04-24 2024-04-17 ViiV Healthcare UK (No.5) Limited Compounds with hiv maturation inhibitory activity
CN109705189B (zh) * 2018-12-29 2020-06-05 中国医学科学院药用植物研究所 具有式i所示结构的三萜衍生物及其制备方法和应用
HRP20231582T1 (hr) 2019-02-11 2024-03-15 Hetero Labs Limited Novi derivati triterpena kao inhibitori hiv-a
WO2020229398A1 (de) 2019-05-14 2020-11-19 Bayer Aktiengesellschaft (1-alkenyl)-substituierte pyrazole und triazole als schädlingsbekämpfungsmittel

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009020732A1 (en) * 2007-08-03 2009-02-12 Advanced Life Sciences, Inc. Lupane-type triterpenoids modified at 30-position and analogues thereof
WO2009100532A1 (en) * 2008-02-14 2009-08-20 Virochem Pharma Inc. NOVEL 17ß LUPANE DERIVATIVES
WO2011153315A1 (en) * 2010-06-04 2011-12-08 Bristol-Myers Squibb Company Modified c-3 betulinic acid derivatives as hiv maturation inhibitors
WO2011153319A1 (en) * 2010-06-04 2011-12-08 Bristol-Myers Squibb Company C-28 amides of modified c-3 betulinic acid derivatives as hiv maturation inhibitors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5869535A (en) 1995-03-21 1999-02-09 The Board Of Trustees Of The University Of Illinois Method and composition for selectively inhibiting melanoma
US5962527A (en) 1995-03-21 1999-10-05 The Board Of Trustees Of The University Of Illinois Method and composition for treating cancers
US5679828A (en) 1995-06-05 1997-10-21 Biotech Research Labs, Inc. Betulinic acid and dihydrobetulinic acid derivatives and uses therefor
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7365221B2 (en) 2002-09-26 2008-04-29 Panacos Pharmaceuticals, Inc. Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
WO2004089357A2 (en) 2003-04-02 2004-10-21 Regents Of The University Of Minnesota Anti-fungal formulation of triterpene and essential oil
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
MXPA06010592A (es) 2004-03-17 2007-06-12 Panacos Pharmaceuticals Inc Sales farmaceuticas de acido 3-o-(3',3'-dimetilsuccinil) betulinico.
TW200628161A (en) 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
WO2008127364A2 (en) 2006-10-13 2008-10-23 Myriad Genetics, Inc. Antiviral compounds and use thereof
US20110144069A1 (en) 2006-10-16 2011-06-16 Myriad Genetics, Incorporated Compounds for treating viral infections
WO2009082819A1 (en) * 2008-01-03 2009-07-09 Virochem Pharma Inc. Novel lupane derivatives
US9067966B2 (en) 2009-07-14 2015-06-30 Hetero Research Foundation, Hetero Drugs Ltd. Lupeol-type triterpene derivatives as antivirals
MA33926B1 (fr) 2009-12-17 2013-01-02 Merck Sharp & Dohme Aminopyrimidines en tant qu'inhibiteurs de la syk
MA34397B1 (fr) 2010-07-02 2013-07-03 Gilead Sciences Inc Dérivés d'acide napht-2-ylacétique dans le traitement du sida
US8846647B2 (en) 2011-01-31 2014-09-30 Bristol-Myers Squibb Company C-17 and C-3 modified triterpenoids with HIV maturation inhibitory activity
RS54352B1 (sr) 2011-01-31 2016-02-29 Bristol-Myers Squibb Company C-28 amini c-3 modifikovanih derivata betulinske kiseline kao inhibitori sazrevanja hiv-a
BR112014006559A2 (pt) * 2011-09-21 2017-03-28 Bristol Myers Squibb Co derivados do ácido betulínico com atividade antiviral
US8889854B2 (en) * 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity
SG11201505639SA (en) * 2013-02-06 2015-08-28 Bristol Myers Squibb Co C-19 modified triterpenoids with hiv maturation inhibitory activity

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009020732A1 (en) * 2007-08-03 2009-02-12 Advanced Life Sciences, Inc. Lupane-type triterpenoids modified at 30-position and analogues thereof
WO2009100532A1 (en) * 2008-02-14 2009-08-20 Virochem Pharma Inc. NOVEL 17ß LUPANE DERIVATIVES
WO2011153315A1 (en) * 2010-06-04 2011-12-08 Bristol-Myers Squibb Company Modified c-3 betulinic acid derivatives as hiv maturation inhibitors
WO2011153319A1 (en) * 2010-06-04 2011-12-08 Bristol-Myers Squibb Company C-28 amides of modified c-3 betulinic acid derivatives as hiv maturation inhibitors

Also Published As

Publication number Publication date
KR20140123584A (ko) 2014-10-22
AU2013221725A1 (en) 2014-10-02
IL234077A (en) 2016-11-30
UY34627A (es) 2013-09-02
US8906889B2 (en) 2014-12-09
WO2013123019A1 (en) 2013-08-22
IL234077A0 (en) 2014-09-30
MX2014009235A (es) 2014-11-10
CN106046106A (zh) 2016-10-26
JP2015510515A (ja) 2015-04-09
EA201491531A1 (ru) 2014-11-28
US20130210787A1 (en) 2013-08-15
CA2864656A1 (en) 2013-08-22
AR089996A1 (es) 2014-10-01
TW201336863A (zh) 2013-09-16
BR112014019672A8 (pt) 2017-07-11
EA024361B1 (ru) 2016-09-30
CL2014002141A1 (es) 2014-10-03
PT2814834T (pt) 2017-12-06
NZ631408A (en) 2015-06-26
AU2013221725B2 (en) 2016-10-27
CN104220451A (zh) 2014-12-17
SG11201404748XA (en) 2014-09-26
MY166793A (en) 2018-07-23
JP6155285B2 (ja) 2017-06-28
CO7061077A2 (es) 2014-09-19
PE20142315A1 (es) 2015-01-16
ZA201406724B (en) 2016-08-31
PH12014501816A1 (en) 2014-11-17
EP2814834A1 (en) 2014-12-24
EP2814834B1 (en) 2017-09-13
ES2656984T3 (es) 2018-03-01
BR112014019672A2 (enExample) 2017-06-20
HK1204608A1 (en) 2015-11-27

Similar Documents

Publication Publication Date Title
CN104220451B (zh) 具有hiv成熟抑制活性的c-3环烯三萜类化合物
JP6186012B2 (ja) C−3アルキルおよびアルケニル修飾ベツリン酸誘導体
TWI574973B (zh) 具有hiv成熟抑制活性之c-17雙環胺三萜類化合物
US11464790B2 (en) Triterpenoids with HIV maturation inhibitory activity
JP2017533937A (ja) オキソルペン誘導体
HK40041853A (en) Triterpenoids with hiv maturation inhibitory activity
HK1232548B (en) Triterpenoids with hiv maturation inhibitory activity, substituted in position 3 by a non-aromatic ring carrying a haloalkyl substituent

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20180521

Address after: The Middlesex County

Patentee after: Health UK fifth Limited

Address before: new jersey

Patentee before: Squibb Bristol Myers Co.

TR01 Transfer of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160629

Termination date: 20200213

CF01 Termination of patent right due to non-payment of annual fee